ArticleFrontiers in cellular and infection microbiology2026
Pre-treatment pathogen testing rates before antimicrobial therapy in emergency departments: a four-year retrospective study from two hospital campuses.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To monitor and analyze the current status and trends in pretreatment pathogen testing rates for antimicrobial therapy in the emergency departments of two campuses of a tertiary hospital, explore key factors influencing pathogen testing rate, and propose improvement strategies. Methods: Data from 534,374 visits from the emergency departments between 2021 and 2024 were collected via the hospital information system, outpatient logs, and laboratory management system. Antibiotic utilization rates and pretreatment pathogen testing rates were calculated. Statistical analyses included chi-square tests, Cochran-Armitage trend tests, Cramer's V, and logistic regression. Results: Over four years, antimicrobial usage increased from 17.95% to 22.59% (Z = 41.79, P < 0.001), whereas the pathogen testing rate remained consistently low at 13.08%-14.17%, with no improvement (Z=-1.70, P = 0.089). The pathogen testing rate at Dongjie Campus was significantly lower than that at East City Campus in all years (P < 0.001). From 2021 to 2023, the pathogen testing rate in internal medicine departments exceeded that in surgical departments, but this trend reversed for the first time in 2024 (internal medicine: 12.42% vs. surgery: 13.86%, P<0.001). Procalcitonin was the primary specimen type, with its proportion declining annually; Mycoplasma pneumoniae testing showed rapid growth; and traditional bacterial culture consistently accounted for less than 5% of the samples. Conclusion: Emergency antimicrobial usage rates have persistently increased, whereas pathogen testing rates have remained chronically low, revealing a prominent contradiction of "high usage, low submission." Significant variations exist across campuses and departments. The submission structure is imbalanced, with severe inadequacies in microbial culture. We recommend establishing a multidisciplinary collaborative management model, strengthening information-based interventions, optimizing submission workflows, and implementing long-term oversight and incentive mechanisms to achieve targeted antimicrobial therapy and antimicrobial resistance control objectives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.